IKT · Inhibikase Therapeutics, Inc.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share.

This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement").

(Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable,

(Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.

Represents shares of common stock, par value $0.001, of the Issuer ("Common Stock") held by Sands Pulse Fund II. Sands Capital Alternatives, LLC ("Sands Alternatives") is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP L.P.") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC ("Sands Pulse GP LLC") is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.

The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the "Option Award"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award.

The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.

The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 9,544 shares vested on the Closing Date, 28,632 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 19,089 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 19,089 shares shall be forfeited.

The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date.

The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

The options vested and became exercisable on February 14, 2025.

The options vested and became exercisable on February 14, 2025.

The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date.

The options vested and became exercisable on February 14, 2025.

The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

The options vested and became exercisable on February 14, 2025.

The options vested and became exercisable on February 14, 2025.

The options vested and became exercisable on February 14, 2025.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.